Faeth Therapeutics (FTH) Treasury Shares (2020 - 2026)

Faeth Therapeutics' (FTH) quarterly Treasury Shares came in at $502.0 in Q2 2026, down 97.99% quarter-over-quarter from $24937.0 in Q1 2026.

Analysis

Faeth Therapeutics (FTH) Treasury Shares (2020 - 2026) Analysis & Trends

Faeth Therapeutics (FTH) has reported Treasury Shares for 2 consecutive years, with $502.0 the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Treasury Shares changed N/A year-over-year to $502.0; the trailing twelve-month figure through Jun 2026 stood at $502.0 (changed N/A YoY), and the FY2020 full-year result was $747.7 million, changed N/A from the prior year.
Treasury Shares slipped to $502.0 in Q2 2026 per FTH's latest filing, from $24937.0 in the prior quarter.
Across five years, Treasury Shares topped out at $24937.0 in Q1 2026 and bottomed at $502.0 in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	36.40 Mn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	-23.80 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Faeth Therapeutics	218.99 Mn	218.99 Mn	-	502.00

Historic Data

Download Data